buyModerate cluster of 5
Matthew Eric Smith bought $250k of Crestline Lending Solutions, LLC
director at Crestline Lending Solutions, LLC. 12,739 shares at an average of $19.63, traded Jul 24, 2026, filed Jul 28, 2026.
Conviction score
51Value
$250k
12,739 shares
Holdings after
12,739
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +13Trade size$250k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNo price history yet
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-26-050139, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | POpen-market purchase Limited Liability Company Units | +12,739 | $19.63 | $250k | 12,739 | Jul 28, 2026 |
Related signals
Other insiders at Crestline Lending Solutions, LLC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | -buy 5 Crestline Lending Solutions, LLC | Bowen S Diehl director | $500k 25,477 shares | - | |
| 50Moderate | -buy 5 Crestline Lending Solutions, LLC | Tom Bavin Chief Development Officer | $200k 10,191 shares | - | |
| 54Moderate | -buy 5 Crestline Lending Solutions, LLC | John Cochran Chief Operating Officer | $150k 7,643 shares | - | |
| 66Notable | -buy 5 Crestline Lending Solutions, LLC | Christopher James Semple Chief Executive Officer | $500k 25,477 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.